For people with newly diagnosed acute myeloid leukemia (AML), the more leukemia cells are destroyed, the better their long-term outcomes. In this study, researchers want to see adding venetoclax to standard chemotherapy (daunorubicin/cytarabine) or giving it with azacitidine works better than standard therapy for getting rid of the small amount of remaining leukemia cells. The people in this study include young adults with intermediate-risk AML.
Venetoclax is in a class of medications called BCL-2 inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein cancer cells need to survive.
If you join this study, you will get one of these regimens of treatment:
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
To join this study, there are a few conditions. You must:
Phase 2
Enrollment: 153 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Birmingham, AL
Los Angeles, CA
Chicago, IL
Springfield, IL
Iowa City, IA
Canton, MI
Omaha, NE
New Brunswick, NJ
Rochester, NY
Winston-Salem, NC
Portland, OR
Portland, OR
Houston, TX
Green Bay, WI
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message